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Abstract

Carbamazepine is an early anticonvulsant still used today in the treatment of
several forms of epilepsy. An active metabolite in the human body contributes to its
pharmacological effect. Carbamazepine metabolism has high inter-individual
variability, such that it is relatively difficult to establish a direct link between dose
and concentration, or between concentration and pharmacological effect.
Carbamazepine is thus a good candidate for therapeutic drug monitoring
(TDM). Good UV specific absorbance and high plasmatic concentrations allow for
the use of UV detection, which is often more accessible than other methods of
detection.
This paper presents several methods used for the detection of carbamazepine in
plasma, methods that are capable of detecting drug and metabolites at adequate
levels/ acceptance criteria. These methods have possible application not only in
pharmacokinetic, bioequivalence, and permeability studies, but also in the
therapeutic drug monitoring of carbamazepine.

Keywords: carbamazepine, therapeutic drug monitoring, bioanalytical method, validation,
epilepsy
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Introduction
Carbamazepine, an iminostilbene drug substance
Epilepsy is a common neurological disorder. The from a chemical point of view, is effective against grand
probability of an individual developing the disorder mal and all forms of epilepsy except petit mal. Its
during a lifetime is between 3% and 5%. Newborn, pharmacological action is similar to phenobarbital,
children, and the elderly have the highest risk of phenytoin, lamotrigine, topiramate, and valproic acid,
developing epilepsy. An epileptic seizure is defined as a Figure 2, (3). It was initially approved in the U.S. for use
paroxysmal discharge of cerebral neurons, followed by as an anti-seizure agent in 1974. It has been employed
obvious clinical phenomena: motor, sensory, and since the 1960’s for the treatment of trigeminal neuralgia
autonomic, with impairment or complete loss of and is now considered a primary drug for the treatment
consciousness. Epilepsy is defined as a condition of partial and tonic-clonic seizures (4).
characterized by repeating seizures (colloquially named
“fits”). A patient should not be diagnosed with epilepsy
until two such non-febrile seizures occur (1).
TDM (therapeutic drug monitoring) may be defined
as the use of drug or metabolite monitoring in body
fluids as an aid to the management of therapy (the term
therapeutic drug management is now also employed as
an alternative description). Patients may need different
doses of a drug to produce optimum pharmacological

Figure 2. Carbamazepine chemical structure

Therapy with antiepileptic drugs should commence

effects, as individuals vary widely regarding drug

only if the risk of future seizures on the patient’s health
absorption, elimination (pharmacokinetics), and effect outweighs the risk of therapy. A premature start of
(pharmacodynamics) (2). The pharmacokinetics and antiepileptic therapy may expose the patient to
pharmacodynamics steps involved in drug action are unnecessary risk tied to the adverse effects of the drugs.
summarized in Figure 1. Most antiepileptic drugs meet Also the social consequences should not be overlooked,
the requirements for therapeutic drug monitoring (TDM) especially in the case of diagnostic errors (for example:
and thus are benefitted by this approach.

the loss of the driver’s license) (5). On the other hand,
waiting too long to treat must also be avoided. There are
insufficient data to support the contention that seizures
affect brain tissue and diminish cognitive capacity, but it
is known that status epilepticus is a contributing factor to
brain injury and death (1).
However, the most compelling reasons to start
antiepileptic treatment are the risk of personal injury, the
risk of causing harm to others, and the psychosocial

Figure 1. Pharmacokinetics and pharmacodynamics
steps involved in drug action; (2), adapted

consequences of untreated epilepsy: low self-esteem,
anxiety, and domestic and employment difficulties (1).
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The choice of the drug used for treatment is bound (65–85%) and is rapidly distributed to all tissues.
determined mainly by its efficacy against the seizures Concentrations in cerebrospinal fluid (CSF) appear to
and the potential adverse effects. Monotherapy is correspond to the concentration of free drug in plasma
preferred.
(4). The drug exhibits auto-induction, which causes the
Carbamazepine (5H- dibenzo [b,f] azepin – 5 - initial low clearance rate to double or triple with
carboxamida) is a popular anticonvulsant and moodcontinued exposure (1, 4, 6).
stabilizing drug used in Europe for many years (4).
Clearance is ensured by hepatic biotransformation
Reports of bone marrow suppression and leucopenia as
(>99%) and to a small degree by renal excretion.
adverse effects delayed the release on the US market
Carbamazepine is metabolized by the hepatic
until 1974, when it was approved for the treatment of
microsomal enzymes system, through oxidation by the
trigeminal neuralgia. It has since become a first line drug
isoforms of cytochrome P450, followed by
against temporal lobe epilepsy and other convulsive
glucuronidation (3).
disorders. It is a derivative of iminostilbene with a
Carbamazepine is metabolized in the liver by the
carbamyl group at the 5 position. The moiety is essential
isoenzymes CYP1A2, CYP3A4, CYP2C8 and CYP2C9,

for the antiepileptic action (6).

Carbamazepine is used mainly in the management of only two of which can be found in the transformation of
epilepsy, bipolar disorder, trigeminal neuralgia, other anti-epileptics (CYP3A4 and CYP2C9). The
attention-deficit
schizophrenia,

hyperactivity
complex

disorder

regional

pain

(ADHD), participation of such a high number of CYP isoforms
syndrome, implies numerous interactions with drugs from different

paroxysmal extreme pain disorder, neuromyotonia, therapeutic classes, through cross inhibition or induction
disorder, borderline, and post-traumatic stress disorder (3).
(6).
Carbamazepine decreases phenytoin metabolism due

Discussion

to competition for CYP2C9 isoform, but also by

1. General data

enzymatic inhibition, which leads to an increase in

Pharmacokinetics
The

pharmacokinetics

plasmatic concentrations, with an increase in toxicity
of

carbamazepine

are (Figure 3). It also exerts enzymatic induction on the

complex. They are influenced by its limited aqueous oxidative enzymatic systems dependent on cytochrome
solubility and by the ability of many anti-seizure drugs, P450 and uridine glucuronyl transferase system (UGT).
including carbamazepine itself,

to increase their Carbamazepine reduces the effectiveness of valproic

conversion to active metabolites by hepatic oxidative acid, clonazepam, ethosuximide, and lamotrigine (3). It
enzymes (4).

also reduces its own metabolism. Thus, the half-life of

Carbamazepine is slowly and erratically absorbed carbamazepine is drastically reduced after repeated
after oral administration with great inter-individual doses. Usually the half-life is between 12 and 24 hours,
variability. Peak concentrations in plasma are usually observed to be shorter in children than in adults (1).
observed 4-8 hours after oral ingestion, but may be

The main metabolite of carbamazepine is the

delayed by as much as 24 hours, especially following pharmacologically active carbamazepine-10,11-epoxide.
administration of a large dose. It is moderately protein It is eliminated mainly as metabolites, through renal
102
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excretion, with only a small part eliminated through spontaneous activity or on responses to iontophoretically
feces. In children carbamazepine clearance is faster with applied GABA or glutamate. The carbamazepine
a high accumulation of active metabolites (1, 3). Other metabolite,
metabolites

identified

in

the

carbamazepine-N-glucuronide,

urine

10,11-epoxycarbamazepine,

also

limits

include sustained repetitive firing at therapeutically relevant

iminostilbene,

and concentrations, suggesting that this metabolite may

several monohydroxy- and trihydroxy-carbamazepine contribute to the anti-seizure efficacy of carbamazepine
isomers (7).

(4).
Toxicology
Carbamazepine is chemically related to tricyclic
antidepressants, like imipramine; thus it exhibits similar
adverse effects: cholinergic effects, convulsions, and
cardiac conduction anomalies. In severe intoxications,

Figure 3. Carbamazepine metabolism

Carbamazepine-10,11-epoxide is as active as the
parent

compound

in

various

animals,

and

its

concentrations in plasma and brain may reach 50% of
those of carbamazepine, especially during the concurrent
administration of phenytoin or phenobarbital. The 10,11epoxide is metabolized further to inactive compounds,
which are excreted in the urine principally as
glucuronides. Carbamazepine is also inactivated by

myoclonus, hypothermia, coma, and respiratory arrest
may occur. Atrioventricular block and bradycardia have
also been reported. It is highly hepatotoxic and can
present

teratogenicity

(spina

bifida

and

cardiac

malformations) (3).
During long-term therapy, the more frequent
untoward effects of the drug include drowsiness, vertigo,
ataxia, diplopia, and blurred vision. The frequency of
seizures may increase, especially with overdose. Other

conjugation and hydroxylation (7).

adverse effects include nausea, vomiting, serious
Pharmacodynamics

hematological

Carbamazepine stabilizes the neuronal membrane agranulocytosis),
(blocking depolarization and hyperpolarization) by (dangerous

toxicity
and
skin

(aplastic
hypersensitivity
reactions,

anemia,
reactions
eosinophilia,

blocking the sodium channels, thereby increasing the lymphadenopathy, splenomegaly). A late complication
excitability and convulsive threshold. It also reduces the of therapy with carbamazepine is retention of water, with
discharge of pathologically modified neurons and limits decreased osmolality and concentration of Na+ in
cell depolarization inside the epileptic center (3).

plasma, especially in elderly patients with cardiac

This effect appears to be mediated by a slowing of disease (4).
the rate of recovery of voltage-activated sodium
channels

from

inactivation.

These

effects

Carbamazepine induces hypersensitivity reactions

of that frequently involve the skin. Approximately 5-10%

carbamazepine are evident at concentrations in the range of patients taking carbamazepine experience cutaneous
of therapeutic drug levels in the CSF of humans. The adverse drug reactions. Carriers of specific HLA variants
effects

of carbamazepine are selective at these are known to be susceptible to carbamazepine-induced

concentrations, in that there are no effects on hypersensitivity reactions. Therefore, HLA testing of
103
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patients can identify those at-risk individuals so that an of antihypertensive drugs) or may use an appropriate
alternative drug can be used (8).
Therapy and posology

laboratory marker (e.g., glucose determination for
hypoglycemic agents or cholesterol/triglycerides levels

In epilepsy, carbamazepine is administered in doses for lipid-lowering drugs) (2).
Dose adjustment is much more difficult (but no less
of 0.8-1.2 g/day for 2-3 times a day for an adult and 0.1necessary) when drug response cannot be rapidly
1 g/day (10-25 mg/kg/day) for children between 1 and
assessed clinically, which is the case for antidepressants.
15 years. The posology can be optimized by therapeutic
Under certain conditions and suitable analytical
drug monitoring (TDM) due to the good correlation
methods, plasma concentration of a drug and/or
between plasmatic concentration and therapeutic effect
metabolite can be determined and may serve as an
(3).
effective and clinically useful surrogate marker of the
Monitoring plasmatic concentration is feasible when
response. However, TDM is not just about the analytical
deemed appropriate from clinical data. The therapeutic
result; rather it assumes multiple determinations at
concentration interval is around 4 to 12 µg/mL (9).
different moments, with the analytical results interpreted
Because determination of free carbamazepine is more
in order to make the best decision for the patient (2).
reliable, concentration in saliva and tears (where
The AGNP (Arbeitsgemeinschaft für Neuropsychocarbamazepine occurs in unbound form) has also been
pharmakologie und Pharmakopsychiatrie) provides a
determined (1).
consensus guideline regarding optimal use of TDM in a
However, there may be no simple relationship
clinical context for psychotropic drugs. They note that
between the dose of carbamazepine and concentrations
the development of new, sensitive analytical techniques
of the drug in plasma. Therapeutic concentrations are
have shown that drug concentrations vary widely due to
reported to be 6-12 μg/mL, although considerable
high inter-individual variability in the pharmacokinetics
variation occurs. Side effects referable to the CNS are
and pharmacodynamics of these drugs by correlating
frequent at concentrations above 9 μg/mL (4). During
plasmatic concentration with dosage and adverse effects
maintenance therapy carbamazepine absorption and
(11). The high inter-individual variability of plasma
clearance are highly variable and its elimination half-life
concentrations is also reported for different drugs, such
may be longer than previously suspected. Sex and racial
as methotrexate, tamoxifen, methadone, and tramadol
differences in clearance may contribute to variable
(12-14), as well as for metabolites used as biomarkers of
dosing requirements and clinical response (10).
exposure (i.e., cotinine). Such findings have encouraged
Discontinuing treatment with carbamazepine is
clinicians to use TDM in combination with
achieved by steadily reducing the dosage so as to avoid
pharmacogenetic testing in order to demonstrate
severe seizures (3).
genetically determined metabolism (15-17).
2. Therapeutic drug monitoring (TDM)

If plasma drug concentrations are to be a useful

Pharmacological effects can be measured with the surrogate marker of response, two premises must be
use of markers—the response of the patient to the satisfied:
treatment. In clinical practice this is straightforward -

The drug concentration in plasma must accurately

when the response is readily measurable. The response

reflect the concentration at the site of action (the

can be a clinical measure (e.g. blood pressure in the case

receptor).
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-

The drug concentration at the receptor should
provide

an

accurate

indication

of

Plasma or serum samples are generally used for

the TDM. Chromatography is the most widely used method,

pharmacological response.

high performance liquid chromatography (HPLC) or

The essential criteria for TDM to be clinically useful gas-chromatography (GC), coupled with various
detectors: UV (although not very sensitive),
may be summarized as follows (2):


Poor correlation existing between the dose given and

the plasma concentration obtained in different patients
(wide inter-individual pharmacokinetic variability).


Good

correlation

existing

between

plasma

fluorescence, MS, MS-MS, or nitrogen-phosphorous
detectors for GC. Also, there is need for sample cleanup—atime-consuming step—in order to remove matrix
effects.
Regarding the methods used in bioanalysis, the FDA

concentration and pharmacological effect in different (US Food and Drug Administration) has issued a
patients

(low

inter-individual

pharmacodynamic guideline (Guidance for Industry – Bioanalytical method

variability); this also implies an established therapeutic validation) in which general recommendations regarding
range of plasma concentrations or a good relationship method validation are presented. The information in the
between plasma concentration and effect.

guidance applies to bioanalytical procedures and



Clinically relevant only for drugs that show immunological and microbiological procedures that are
significant toxic or undesirable effects at plasma performed for the quantitative determination of drugs
concentrations only slightly above those required for and/ or metabolites as well as therapeutic proteins in
biological matrices, such as blood, serum, plasma, urine,
useful effect (low therapeutic index).
tissue, and skin (18).
 TDM is redundant for drugs where there is a better
Validating
bioanalytical
methods
includes
clinical marker of both the desired effect and any
performing all the procedures that demonstrate that a
associated adverse effects.
particular method used for quantitative measurement of
 Treatment is expected to be long-term.
analytes in a given biological matrix (e.g., blood,
For effective TDM practice, analytical methods of plasma, serum, or urine) are reliable and reproducible for
adequate sensitivity are necessary to correctly evaluate the intended use. Fundamental parameters for this
the drug concentration levels in body fluids. Selectivity validation include the following: accuracy, precision,
is also an issue due to co-medication (drugs administered selectivity, sensitivity (limits of quantitation),
simultaneously may interfere with the assay). Because

reproducibility, and stability (18).

carbamazepine is metabolized to an active compound, 3. Bioanalytical methods for
the challenge of developing a suitable method is even carbamazepine and metabolite
greater. In order to have all the information to assess

determination

of

In Table 1 the acceptance criteria for validation

pharmacological and toxicological effects, both the parameters of bioanalytical methods are presented.
parent compound and the metabolite must be correctly These criteria follow the Guidance for Industry –
assayed in order to make good decisions regarding Bioanalytical method validation Draft Guidance from
patient therapy.

2013 provided by the FDA/CDER (18).
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Table 1. Acceptance criteria for method validation parameters according to FDA/CDER Guidance for Industry (DRAFT) (18)

Parameter

Acceptance criteria

Accuracy (recovery %)

Recovery of 100%±15% (±20% for LLoQ)

Precision (coefficient of variation CV %)

Relative standard deviation of 15% (20% for LLoQ)

Linearity and range

Calibration curve with a correlation factor (R) NLT 0.999

Selectivity

No interference from biological matrix, metabolites and
concomitant medication

Limit of quantitation

LLoQ an ULoQ (consistent with accuracy, precision and
linearity)

Stability

Freeze and Thaw stability / Long-term stability

The methods reported in the literature are mostly specific method is required, MS detection can be
RP-HPLC (reversed-phase high performance liquid employed.
chromatography).

The

chromatographic

columns,

Regardless of the detection method used, sample

stationary phases, are C18 (octadecylsilane) and the preparation is a very important step. Sample cleanup is
mobile phases used are usually simple, polar, binary essential

to

lower

the

noise

obtained

in

the

mixtures between water and an organic solvent chromatogram and to reduce potential damage done to
(methanol or acetonitrile). Acidic modifiers are added in various parts of the equipment. Methods used for sample
some methods: formic acid (19), phosphoric acid (20, preparation vary from liquid-liquid extraction (31-33),
21), acetic acid (22), or heptafluorobutyric acid (23). The solid phase extraction (34), and protein precipitation (35elution system is isocratic, with one method reported to 37). All methods presented use plasma or other
have gradient elution (23). Phosphate buffers of different biological samples, although one method is used for
pH are used as an aqueous mobile phase in some carbamazepine
methods (24-28).

determination

in

pharmaceutical

formulations. This method however could be applied to

Ternary mixtures are also widely used as a mobile biological fluids (38).
phase(29, 30).One method reported the use of a

Some methods have used internal standards for the

diisopropyl-C14 column which is suitable for analyzing evaluation of carbamazepine assay in the biological
very

basic

and

Chromatography

polar

compounds

methods

are

not

(26).

Gas- fluid, which is usually plasma. Some methods were used

suitable

for for cell permeability studies.Another chromatographic

carbamazepine determination due to its susceptibility to method reported for the assay of carbamazepine is
thermal degradation.
Detection

is

spectrophotometric

HPTLC (high performance thin-layer chromatography),
achieved

by

methods

(UV)

the
with

use

of used for quantitation in formulation and for in-vitro

various dissolution studies (39).

wavelengths, between 210 nm and 285 nm. MS-MS

UV spectrophotometric methods have been reported

detection is also used in two of the methods (19, 22). UV for carbamazepine in pharmaceutical formulations (40,
detection is sufficient as the therapeutic ranges of 41). These methods are not applicable to biological
carbamazepine and its metabolite are well within the samples because they fall short with regards to
sensitivity limits of UV detection. However, if a very specificity: interference from sample matrix or co106
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medication is highly possible and differentiation
between carbamazepine and metabolites is not possible.
Immunoassays

have

also

been

reported

Also, where results reported in the articles did not
match the parameters reported in the present tables,

for calculations were performed to standardize the values

determination in plasma (31). In one case immunoassays presented, in order to allow an objective comparison of
were used to generate mathematical equations for the methods (e.g., if results for precision were presented
determination of carbamazepine and its metabolite in as standard deviation and the average was also reported,
plasma (19).

a simple calculation was performed in order to report

Tables 2 to 5 present a summary of the relative standard deviation in the tables).
chromatographic methods presented in this article. The

Results for accuracy are presented as minimum and

parts left blank (with a dash) indicate that the validation maximum values obtained for inter-day and intra-day,
parameter was either not performed or not reported.

where applicable.

Table 2. Carbamazepine and metabolite determination by HPLC (I)
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Table 3. Carbamazepine and metabolite determination by HPLC (II)
HPLC methods with UV detection

Parameter
(Reference)

Stationary phase
–
chromatographic
column

(35)

(21)

(23)

(33)

C18

C18

C18

C18

Gradient

A=Water pH=3
(orthophosphoric acid)
Mobile phase

Methanol:Water
= 50:50

B=Acetonitrile:Methanol=50:5
0
A:B=58:42

A = 1%
isopropanol +
0.01%
heptafluorobutyric
acid in water

Water:Acetonitril
e=70:30

B = 1%
isopropanol +
0.01%
heptafluorobutyric
acid in acetonitrile

Detection

285 nm

205 nm

280 nm

210 nm

Internal standard

Propylparaben

-

-

Methyl-phenylphenytoin

Limit of
detection

-

0.67 μg/mL

0.03 μg/mL

0.15 μg/mL

Limit of
quantitation

0.5 µg/mL

2.24 μg/mL

0.10 μg/mL

0.3 μg/mL

Linearity and
range

0.5 – 40 µg/mL

5 - 100 μg/mL

0.993 - 198.6

0.3 - 20.0 μg/mL

Precision
(coefficient of
variation CV %)

<3.7%

0.15 - 1.13%

2.24%-3.78%

0.3 – 7.4%

Accuracy
(recovery %)

97.53%103.58%

99.79-101.23

98.69%

98.5%

Sample
preparation

Protein
precipitation

-

-

Liquid-liquid
extraction

Sample type

Plasma

Permeability studies

Permeability
studies

Plasma

μg/mL
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Table 4. Carbamazepine and metabolite determination by HPLC (III)
HPLC methods with UV detection

Parameter
(Reference)

(37)

(24)

(36)

(25)

(26)

C18

C8

C18

C18

Diisopropyl –
C14 (Bonus
RP)

Mobile phase

Methanol:Water
= 50:50

Acetonitrile :
Isopropyl alcohol :
phosphate buffer
pH 3 = 36:15:49

Methanol:Water
= 50:50

10 mM
Phosphate
buffer pH 7.0 :
Acetonitrile =
70:30

Acetonitrile
: phosphate
buffer pH
7.5 = 45:55

Detection

285 nm

220 nm

285 nm

210 nm

241 nm

Internal standard

-

Diclofenac
sodium

-

Phenobarbital

-

Limit of detection

-

0.05 µg/mL

-

0.02 µg/mL

0.006
µg/mL

Limit of quantitation

0.5 µg/mL

0.1 µg/mL

0.5 µg/mL

0.2 µg/mL

0.02 µg/mL

Linearity and range

0.5 – 40 µg/mL

0.1 – 8.0 µg/mL

0.5 – 40 µg/mL

0.2 – 25 µg/mL

-

Precision (coefficient
of variation CV %)

2.42% – 11.79%

4.17% – 12.78%

2.42% – 11.79%

< 7.96%

Accuracy (recovery
%)

93.18% –
104.49 %

85.00%–100.0%

93.18% – 104.49
%

92.09% –
108.5%

78.8% –
106.3%

Sample preparation

Protein
precipitation

Protein
precipitation and
liquid-liquid
extraction

Protein
precipitation

Solid-phase
extraction

Liquidliquid
extraction

Sample type

Blood

Plasma

Intestinal sac
samples

Plasma

Serum

Stationary phase –
chromatographic
column

6.2% 7.1%
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Table 5. Carbamazepine and metabolite determination by HPLC (IV)
Parameter

HPLC methods with UV detection

(Reference)

(27)

(22)

(29)

(30)

(28)

C18

C18

C18

C18

C18

Mobile phase

5.2 mM
Phosphate buffer
pH 3 :
Acetonitrile =
70:30

Water : Acetonitrile
: Acetic acid = 74.5
: 25 : 0.5

Acetonitrile : Methanol
: Water = 18 : 19: 63

Water :
Methanol :
Acetonitrile =
69 : 25: 6

Phosphate buffer
25 mM pH 4.6 :
Methanol :
Acetonitrile = 55 :
35: 10

Detection

237 nm

MS (ion-trap)

210 nm

215 nm

235 nm

Internal standard

-

Oxcarbamazepine

10-11dihydrocarbamazepine

Primidone

-

-

0.0015 – 0.0016
µg/mL

0.01 µg/mL

0.005 µg/Ml

Stationary phase –
chromatographic
column

0.002 µg/mL for CBZ
Limit of detection

0.0002 µg/mL

-

0.003 µg/mL for
metabolite
0.01 µg/mL for CBZ

Limit of
quantitation

0.0005 µg/mL

5.0 ng/mL

Linearity and
range

0.0005 – 0.2
µg/mL

about 5.0 - 500.0
ng/mL

Precision
(coefficient of
variation CV %)

7.1%

Accuracy
(recovery %)

0.005 µg/mL for
metabolite
0.01 – 10 µg/mL for
CBZ

0.1 – 15
µg/mL for
CBZ

0.005 – 0.2 µg/mL

0.005 – 5 µg/mL for
metabolite

0.1 – 5
µg/mL for
metabolite

0.74% - 3.81%

0.9% - 16.6%

0.8% - 17.3%

5.8% - 6.9%

78.6 % - 98.5%

94.65% - 104.28%

92.6% - 104.2%

87.2% %114.6

95.8% - 98.0%

Sample
preparation

Dispersive liquidliquid
microextraction

Protein
precipitation

Liquid-liquid extraction

Liquid-liquid
extraction

Dispersive liquidliquid
microextraction

Sample type

Plasma, urine and
water

Plasma

Plasma

Cell culture

Plasma and urine
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E. Comparative effectiveness of levetiracetam,
valproate and carbamazepine among elderly patients

Conclusions
The

with newly diagnosed epilepsy: subgroup analysis of

pharmacokinetics
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carbamazepine

are

complex and are influenced by multiple factors such as
its limited aqueous solubility and the ability of many
anti-seizure drugs (including carbamazepine itself) to

the randomized, unblinded KOMET study. BMC
Neurol. 2016; 16(1): 149. PMID: 27552848,

DOI:

10.1186/s12883-016-0663-7
5. Moagar-Poladian
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Folea

V,

Paunica

M.

Competitiveness of EU member states in attracting

increase their conversion to active metabolites by hepatic

EU funding for research and innovation. Romanian

oxidative enzymes.

Journal of Economic Forecasting. 2017; 20(2): 150-

The methods described above have adequate

167.

sensitivity, capable of detecting carbamazepine and 6. Tolbert D, Cloyd J, Biton V, Bekersky I, Walzer M,
epoxy-metabolite at adequate levels, and fulfill all

Wesche D, Drummond R, Lee D. Bioequivalence of

validation acceptance criteria. These methods should
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applications

not

only

in
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